A director at Abbvie Inc sold 66,500 shares at 186.520USD and the significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...
Moody's Ratings (Moody's) affirmed the ratings of AbbVie Inc. ("AbbVie") including the A3 senior unsecured notes, A3 issuer rating and the Prime-2 senior unsecured commercial paper rating. At the same time, we revised AbbVie's outlook to positive from stable. The change in AbbVie's outlook to posi...
Regenerative medicine remains an extremely exciting area of healthcare with vast investment potential. In spite of the usual setbacks in valuation and strategy, the sub-sector has pivoted and the market remains innovative and attracts investment capital. Rather than replace entire tissues, which is a complex activity, we believe the immediate future for stem cells is more likely to be in the successful stimulation of the bodies on repair mechanisms. Within regenerative medicine we believe there ...
Moody's Investors Service ("Moody's") affirmed the ratings of AbbVie Inc. ("AbbVie") including the A3 senior unsecured notes, issuer rating and the Prime-2 senior unsecured commercial paper ratings. The outlook is maintained at stable. These actions follow the announcement that AbbVie will acquire C...
Moody's Investors Service commented that AbbVie Inc.'s announcement that it will acquire ImmunoGen, Inc. for approximately $10.1 billon will enhance its oncology franchise by adding the approved drug Elahere to AbbVie's portfolio. The acquisition also brings oncology pipeline opportunities including...
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
Moody's Investors Service (Moody's) upgraded the senior unsecured long-term ratings of AbbVie Inc. (AbbVie) to A3 from Baa1. At the same time, Moody's affirmed AbbVie's Prime-2 short-term commercial paper rating. Following these actions, the outlook is stable. "The rating upgrade results from ongo...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.